New drug tariffs bring major changes to U.S. medicine imports

Section 232 tariffs reshape drug imports

A new federal tariff policy is changing how patented medicines enter the United States. The Section 232 pharmaceutical tariffs can reach 100% for covered imports, depending on the manufacturer, country of origin, and approved agreements.

The policy does not mean every prescription will double in price. Retail costs depend on insurers, rebates, pharmacies, supply contracts, and whether a drug qualifies for exemptions or special treatment.

Section 232 tariffs include exceptions

The Section 232 pharmaceutical tariffs are broad, but several important exceptions limit their reach. Generic medicines and biosimilars are not subject to these tariffs at this time, while certain specialty products may also qualify for zero-duty treatment.

Patented pharmaceutical products from the European Union, Japan, South Korea, Switzerland, and Liechtenstein generally face a 15% rate. U.K.-origin pharmaceutical products receive separate treatment under the U.S.-U.K. pharmaceutical agreement, which provides Section 232 tariff exemptions for qualifying U.K. products.

Section 232 tariffs reward U.S. investment

The Section 232 pharmaceutical tariffs offer lower rates to companies that commit to making medicines in the United States. Manufacturers with approved onshoring plans can qualify for a 20% rate instead of the 100% rate.

Companies that qualify under the onshoring provisions and enter into approved most-favored-nation pricing agreements can receive zero-tariff treatment through January 20, 2029. The administration says these incentives are meant to strengthen domestic manufacturing and supply security.

A 100% tariff does not double bills

A 100% tariff sounds like a prescription could cost twice as much, but that is not how retail drug pricing works. The tariff applies to the customs value of covered imports, not automatically to a patient’s pharmacy price.

Manufacturers, wholesalers, insurers, pharmacy benefit managers, and pharmacies influence final costs. Some companies may absorb part of a tariff, adjust supply chains, or qualify for lower rates.

Fun fact: Medicare Part D introduced a $2,000 annual out-of-pocket cap for covered prescription drugs in 2025.

Generics are protected for now

For many patients, generic drugs and biosimilars are currently kept outside the Section 232 pharmaceutical tariffs. That matters because generics account for most prescriptions filled in the United States.

The exemption does not guarantee every medicine will stay unaffected. Brand-name products without generic alternatives may face different tariff treatment, while future policy changes could revisit generic imports after government review of supply and national security concerns.

Fun fact: FDA-approved generics must meet the same standards for quality, strength, purity, and stability as brand-name medicines.

Some drugmakers secured zero rates

Several large pharmaceutical companies have agreements that can shield qualifying imports from the new tariffs. The White House annex lists companies, including Merck, Novo Nordisk, Eli Lilly, Novartis, Sanofi, and others, with specific arrangements.

Those agreements combine commitments involving U.S. production and drug pricing. Those company-specific agreements can provide zero-tariff treatment for qualifying imports under their terms so that tariff exposure can differ even among patented drugs produced by major manufacturers.

Ozempic and Wegovy have protection

Novo Nordisk is listed among the pharmaceutical companies with a Section 232 agreement recognized by the White House. Under the proclamation, qualifying imports covered by such agreements can receive preferential or zero tariff treatment, depending on the agreement’s terms.

That means it would be misleading to assume that drugs such as Ozempic or Wegovy will automatically double in price because of the 100% tariff headline. The tariff treatment for a particular shipment can depend on the company agreement, country of origin, and other applicable rules. At the same time, patient costs also depend heavily on insurance and pharmacy benefits.

Keytruda avoids the standard rate

Merck is also listed among the companies with a Section 232 pharmaceutical agreement. Qualifying imports covered by that agreement can receive more favorable tariff treatment than the headline 100% rate.

It would therefore be inaccurate to assume that Keytruda’s patient price will automatically double due to the tariff policy. Patient costs depend on insurance coverage, treatment setting, negotiated rates, assistance programs, and the tariff treatment that actually applies to the imported product.

Trade partners get different rates

Country of origin matters for many patented medicines. Covered products from the European Union, Japan, South Korea, Switzerland, and Liechtenstein face a 15% Section 232 tariff under trade arrangements.

The United Kingdom has separate treatment under its pharmaceutical agreement with the United States, which provides Section 232 tariff exemptions for qualifying U.K.-origin pharmaceutical products.

Specialty drugs have extra safeguards

The proclamation creates zero-tariff pathways for certain specialty medicines when specified trade or urgent-health criteria are met. Commerce can also approve qualifying specialty products when it determines that they address an urgent U.S. health need.

Those safeguards are meant to reduce disruption for products with limited substitutes or urgent medical importance.

Patients could feel indirect effects

Even when a tariff raises an importer’s costs, the effect on patients may appear indirectly rather than as an immediate price increase at the pharmacy. Insurers and employers could respond with premiums, formularies, copays, or coverage.

Any change will depend on the medicine and the supply chain. Patients using drugs covered by agreements, exemptions, or lower country rates may see little tariff-related change in what they personally pay.

The goal is more U.S. manufacturing

The administration says the tariff system aims to encourage drugmakers to build manufacturing capacity inside the United States. Companies with approved onshoring plans receive lower rates, while those without qualifying agreements can face higher tariffs.

The administration says the policy is intended to strengthen supply security and encourage domestic investment. Outside analysts and industry groups have raised concerns that tariffs can raise import costs or complicate supply chains before new U.S. manufacturing capacity comes online.

For another healthcare update tied to drug costs, Medicaid savings, and patient access, see why a new program is cutting prescription prices for millions of Americans.

Check coverage before expecting a jump

Patients taking brand-name medicines should not assume their next refill will suddenly cost twice as much. The tariff rules vary by company, country, drug category, and agreement, while insurance coverage can change out-of-pocket costs.

Anyone concerned about a prescription can check their plan formulary, ask a pharmacist about covered alternatives, and review manufacturer assistance programs. Effects will differ from one medicine to another and from one patient to another.

For another prescription drug update tied to medication costs, affordability, and federal policy, see why TrumpRx may not solve America’s high-price problem.

How do you think the new pharmaceutical tariffs could affect prescription costs in the U.S.? Share your thoughts and drop a comment.

This slideshow was made with AI assistance and human editing.

Read More From This Brand:

• Connecticut caps generic drug price hikes, and the pharma industry is fighting it
  A new tariff threat targets patented drugs and puts pharma on a deadline
• JPMorgan employees can now sue over prescription drug costs